No Longer Business as Usual: FDA Exceptionalism, Commercial Speech, and the First Amendment (Open Access)

Food and Drug Law Journal | Volume 73 | Number 4

No Longer Business as Usual: FDA Exceptionalism, Commercial Speech, and the First Amendment (Open Access)2021-07-22T15:39:58-04:00

Alternative Organic: Legal Issues in Marketing Uncertified Organic Products

Food and Drug Law Journal | Volume 73 | Number 4

Alternative Organic: Legal Issues in Marketing Uncertified Organic Products2021-04-21T10:29:30-04:00

How Might Manufacturers of E-Cigarettes Get New Product and MRTP Orders from FDA More Quickly and Easily?

Food and Drug Law Journal | Volume 73 | Number 4

How Might Manufacturers of E-Cigarettes Get New Product and MRTP Orders from FDA More Quickly and Easily?2021-04-21T10:39:15-04:00

The Responsible Corporate Officer Doctrine: Protections are Needed Despite DOJ’s Cautious Approach

Update Magazine | December 2018/January 2019

The Responsible Corporate Officer Doctrine: Protections are Needed Despite DOJ’s Cautious Approach2019-03-01T10:14:17-05:00

JUUL in Schools: Can FDA Close the Youth On-Ramp While Still Maintaining the Off-Ramp for Adult Smokers?

Update Magazine | December 2018/January 2019

JUUL in Schools: Can FDA Close the Youth On-Ramp While Still Maintaining the Off-Ramp for Adult Smokers?2019-03-01T10:20:19-05:00

A Storm Is Brewing: What Happened to the Generic Pharmaceutical Anti-Trust Price Fixing Criminal Investigation?

Update Magazine | December 2018/January 2019

A Storm Is Brewing: What Happened to the Generic Pharmaceutical Anti-Trust Price Fixing Criminal Investigation?2019-03-01T10:18:58-05:00

Gene Therapy – FDA Takes Steps Toward Clarifying Scope of Orphan Drug Exclusivity

Update Magazine | December 2018/January 2019

Gene Therapy – FDA Takes Steps Toward Clarifying Scope of Orphan Drug Exclusivity2019-03-01T10:19:31-05:00
Go to Top